Skip to main content
SpringerLink
Log in

Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors

  • Chapter
Abdominal Neuroendocrine Tumors

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 933 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6):707–712

    Article  PubMed  Google Scholar 

  2. Niederle MB, Hackl M, Kaserer K, Niederle B (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17(4):909–918

    Article  PubMed  Google Scholar 

  3. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72

    Article  CAS  PubMed  Google Scholar 

  4. Reubi JC, Schär JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282

    Article  CAS  PubMed  Google Scholar 

  5. Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with[111In-DTPA-D-Phel]and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8):716–731

    Article  CAS  PubMed  Google Scholar 

  6. Kowalski J, Henze M, Schuhmacher J et al (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111 In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5(1):42–48

    PubMed  Google Scholar 

  7. Bombardieri E, Giammarile F, Aktolun C et al (2010) 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37(12):2436–2446

    Article  PubMed  Google Scholar 

  8. Bombardieri E, Ambrosini V, Aktolun C et al (2010) 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37(7): 1441–1448

    Article  PubMed  Google Scholar 

  9. Virgolini I, Ambrosini V, Bomanji JB et al (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37(10):2004–2010

    Article  PubMed  Google Scholar 

  10. Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) EV/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354

    Article  CAS  PubMed  Google Scholar 

  11. Velikyan I, Sundin A, Sörensen J et al (2014) Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 55(2):204–210

    Article  CAS  PubMed  Google Scholar 

  12. Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy — The Bad Berka Experience. Theranostics 2(5):437–447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Koopmans KP, de Vires EG, Kema IP et al (2006) Staging of carcinoid tumor with [18F] DOPA PET: a prospective diagnostic accuracy study. Lancet Oncol 7(9):728–734

    Article  CAS  PubMed  Google Scholar 

  14. Ambrosini V, Tomassetti P, Rubello D et al (2007) Role of [18F]Dopa PET/CT imaging in the management of patients with 111In pentetreotide negative GEP tumors. Nucl Med Commun 28(6):473–477

    Article  PubMed  Google Scholar 

  15. Treglia G, Cocciolillo F, de Waure C et al (2012) Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a metaanalysis. Eur J Nucl Med Mol Imaging 39(7): 1144–1153

    Article  PubMed  Google Scholar 

  16. Kroiss A, Putzer D, French A et al (2013) A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging 40(12): 1800–1808

    Article  CAS  PubMed  Google Scholar 

  17. Havekes B, Lai EW, Corssmit EP et al (2008) Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 52(4):419–429

    CAS  PubMed  Google Scholar 

  18. Wieland DM, Wu J, Brown LE et al (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 21(4):349–353

    CAS  PubMed  Google Scholar 

  19. Sisson JC, Shapiro B, Beierwaltes WH et al (1984) Radiopharmaceutical treatment of 30 malignant pheochromocytoma. J Nucl Med 25(2): 197–206

    CAS  PubMed  Google Scholar 

  20. Furuta N, Kiyota H, Yoshigoe F et al (1999). Diagnosis of pheochromocytoma using [123I]-46 compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 6:228–247

    Article  Google Scholar 

  21. Shapiro B, Gross MD, Shulkin B (2001) Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12(10):469–475

    Article  CAS  PubMed  Google Scholar 

  22. Bhatia KS, Ismail MM, Sahdev A et al (2008) 123I-metaiodobenzylguanidine 1 (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxford) 69(2): 181–188

    Article  Google Scholar 

  23. Timmers HJ, Kozupa A, Chen CC et al (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25(16): 2262–2269

    Article  PubMed  Google Scholar 

  24. Milardovic R, Corssmit EP, Stokkel M (2010) Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 91(1):94–100

    Article  CAS  PubMed  Google Scholar 

  25. Naji M, Zhao C, Welsh SJ et al (2011) 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 13(4):769–775

    PubMed  Google Scholar 

  26. Naji M, Al-Nahhas A (2012) Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging 39(Suppl 1):S61–S67

    Article  PubMed  Google Scholar 

  27. Safford SD, Coleman RE, Gockerman JP et al (2004) Iodine 131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101(9): 1987–1993

    CAS  PubMed  Google Scholar 

  28. Khan MU, Morse M, Coleman RE (2008) Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 52(4):441–454

    CAS  PubMed  Google Scholar 

  29. Buscombe JR, Cwikla JB, Caplin MR et al (2005) Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumors depends on initial response. Nucl Med Commun 26(11):969–976

    Article  CAS  PubMed  Google Scholar 

  30. Binderup T, Knigge U, Loft A et al (2010) 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978–985

    Article  CAS  PubMed  Google Scholar 

  31. Severi S, Nanni O, Bodei L et al (2013) Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(6):881–888

    Article  CAS  PubMed  Google Scholar 

  32. Kwee TC, Basu S, Saboury B et al (2011) A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 38(6): 1158–1170

    Article  PubMed  Google Scholar 

  33. Sansovini M, Severi S, Ianniello A et al (2017) Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE. Eur J Nucl Med Mol Imaging 44(3):490–499

    Article  CAS  PubMed  Google Scholar 

  34. Sundin A, Eriksson B, Bergström M et al (2000) Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27(1):33–41

    Article  CAS  PubMed  Google Scholar 

  35. Krenning EP, Bakker WH, Breeman WA et al (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1(8632):242–244

    Article  CAS  PubMed  Google Scholar 

  36. Gibril F, Reynolds JC, Doppman JL et al (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125(1):26–34

    Article  CAS  PubMed  Google Scholar 

  37. Chiti A, Fanti S, Savelli G et al (1998) Comparison of somatostatin receptor imaging computed tomography and ultrasound in the clinical management of neuroendocrine gastroentero-pancreatic tumours. Eur J Nucl Med 25(10): 1396–1403

    Article  CAS  PubMed  Google Scholar 

  38. Kwekkeboom DJ, Kam BL, van Essen M et al (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17(1):R53–R73

    Article  CAS  PubMed  Google Scholar 

  39. Valkema R, De Jong M, Bakker WH et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med 32(2): 110–122

    Article  PubMed  Google Scholar 

  40. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (12):2754–2762

    Article  CAS  PubMed  Google Scholar 

  41. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30(5):781–793

    Article  CAS  PubMed  Google Scholar 

  42. Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39(Suppl 1):S52–S60

    Article  PubMed  Google Scholar 

  43. Castellucci P, Pou Ucha J, Fuccio C et al (2011) Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52(6):886–890

    Article  PubMed  Google Scholar 

  44. Haug AR, Auernhammer CJ, Wängler B et al (2010) 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9): 1349–1356

    Article  CAS  PubMed  Google Scholar 

  45. Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518

    Article  CAS  PubMed  Google Scholar 

  46. Srirajaskanthan R, Kayani I, Quigley AM et al (2010) The role of 68Ga DOTATATE PET in patients with neuroendocrine tumor and negative or equivocal finding on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51(6):875–882

    Article  CAS  PubMed  Google Scholar 

  47. Prasad V, Ambrosini V, Homman M et al (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37(1):67–77

    Article  CAS  PubMed  Google Scholar 

  48. Strosberg J, El-Haddad G, Wolin E et al (2017). Phase 3 trial of 177Lu-DOTATE for midgut neuroendocrine tumors. N Engl J Med 376(2): 125–135

    Article  CAS  PubMed  Google Scholar 

  49. Johnbeck CB, Knigge U, Loft A et al (2017) Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58(3):451–457

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Cancer Center Institute Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy

    Stefano Severi

Authors
  1. Stefano Severi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Severi .

Editor information

Editors and Affiliations

  1. Department of Surgery, Division of General Surgery, S. Eugenio Hospital, Rome, Italy

    Massimo Carlini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag Italia

About this chapter

Cite this chapter

Severi, S., Paganelli, G. (2018). Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors. In: Carlini, M. (eds) Abdominal Neuroendocrine Tumors. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-3955-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-3955-1_8

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-3954-4

  • Online ISBN: 978-88-470-3955-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation